In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...
1d
MedPage Today on MSNApproved Sickle Cell Drug Fails to Beat Placebo in TrialCrizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.
2d
MedPage Today on MSNAvoidable Cancers After Colonoscopy; Real-World Rinvoq Data; Drug Flops in IBS TrialResearchers in Gastroenterology evaluated strategies for preventing avoidable colorectal cancers after colonoscopy. In ...
We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...
Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.
CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with Lewy ...
The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
GlobalData on MSN3d
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I successGilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...
5d
Clinical Trials Arena on MSNMerck KGaA’s lupus drug fails in SLE cohort of Phase II trialMerck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...
Also Read: Weight Loss Drugs Soar While Global Obesity Rates ... In December, in the REDEFINE 1 Phase 3 trial, CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results